Nexentis Gains U.S. Trademark for MITOLINE Drug Discovery Algorithm
NXTS•Nexentis’s subsidiary MitoCareX has received U.S. trademark registration for its MITOLINE sequence analysis algorithm, designed to generate 3D homology models of mitochondrial SLC25 carrier proteins. This IP milestone strengthens the company’s discovery engine identity and supports its precision oncology and inflammatory-metabolic drug pipeline development.
1. U.S. Trademark Approval for MITOLINE
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies, secured official U.S. trademark registration from the USPTO for its proprietary algorithm platform MITOLINE™, marking a key intellectual property milestone for the company.
2. MITOLINE Algorithm Capabilities
MITOLINE™ is a sequence analysis and alignment algorithm engineered to prepare mitochondrial SLC25 carrier proteins for reliable 3D homology modeling, systematically aligning and annotating crucial amino acid sequences to generate robust comparative models.
3. Strategic Impact on Drug Pipeline
The trademark registration reinforces MITOLINE™ as a strategic asset that differentiates Nexentis’s discovery engine, underpinning its precision oncology and inflammatory-metabolic small molecule programs and enhancing potential licensing and collaboration opportunities.
